Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Obtain key information regarding the latest in pharmaceutical research from Informa Pharma Intelligence.
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects (which you can still access below). Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Examine the most successful new active substances (NASs) that hit the market for the first time in 2017. Find out:
Pharmaprojects’ analysts have compiled a compelling view of R&D, past, present, and future. Download your free report today, and discover:
A total pipeline overview, including an overview by phase
Which companies have the most drugs currently in the pipeline
The top therapeutic focus in R&D pipelines
A view of the types of drugs in the pipeline – are biologics the wave of the future?
The top mechanisms of action and targets of investigation
Outlook for the future: what’s in store?
Scrip
18 May 2018
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
Topic Brexit Business strategies
Scrip
By Emily Hayes 18 May 2018
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
Topic Cancer
Pink Sheet
By Cathy Kelly 18 May 2018
Medicare begins analysis process for CAR-T cancer therapies in response to a request from United Healthcare for a national coverage policy.
Topic Cancer Cell and gene therapy
Pink Sheet
By Ian Schofield 18 May 2018
Gedeon Richter’s uterine fibroid drug, Esmya (ulipristal acetate), is expected to be the subject of a safety recommendation by the EMA’s pharmacovigilance committee this week.
Datamonitor Healthcare
By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deal trends
Trialtrove
By Christine Blazynski, PhD 16 May 2018
As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.
Topic Clinical trials
Scrip
By Mandy Jackson 16 May 2018
Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.
Scrip
By Emily Hayes 16 May 2018
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
Topic Cancer
Medtech Insight
15 May 2018
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market
Topic Cancer
Medtech Insight
By Amanda Maxwell 15 May 2018
Belgium is introducing new registration requirements for medical device and IVD operators June 17, ahead of the full application of the EU's medtech regulations and new Eudamed medical device database.
Topic Business strategies
Pharmaprojects, Citeline
By Ian Lloyd 15 May 2018
Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.
Topic Research
Topic Cell and gene therapy
Scrip
By Jessica Merrill 15 May 2018
CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.
Topic FDA Drug approval
Pink Sheet
By Brenda Sandburg 15 May 2018
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.
Topic Alzheimers
Datamonitor Healthcare
By Jack Allen 15 May 2018
Jack Allen, Senior Analyst, Cardiovascular and Metabolic, Datamonitor Healtcare, leads the webinar. Topics covered: Overview of the Dyslipidemia Market Treatment Options Pipeline Therapies in Development Prescribing Trends Dyslipidemia Forecast.
Topic Dyslipidaemia
Scrip
21 May 2018
Pink Sheet
21 May 2018
Pink Sheet
21 May 2018
Pink Sheet
21 May 2018
Medtech Insight
21 May 2018
Scrip
21 May 2018
Medtech Insight
21 May 2018
Medtech Insight
21 May 2018
Medtech Insight
21 May 2018
In Vivo
21 May 2018
Pink Sheet
21 May 2018
Medtech Insight
21 May 2018
Medtech Insight
21 May 2018
Scrip
21 May 2018
Pink Sheet
21 May 2018
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Key benefits:
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
